Compare · BIOA vs NVO
BIOA vs NVO
Side-by-side comparison of BioAge Labs Inc. (BIOA) and Novo Nordisk A/S (NVO): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both BIOA and NVO operate in Biotechnology: Pharmaceutical Preparations (Health Care), so they compete in similar markets.
- NVO is the larger of the two at $195.92B, about 244.3x BIOA ($801.9M).
- Over the past year, BIOA is up 299.1% and NVO is down 45.1% - BIOA leads by 344.2 points.
- BIOA has been more active in the news (10 items in the past 4 weeks vs 8 for NVO).
- NVO has more recent analyst coverage (25 ratings vs 15 for BIOA).
- Company
- BioAge Labs Inc.
- Novo Nordisk A/S
- Price
- $18.06+9.65%
- $43.88-0.20%
- Market cap
- $801.9M
- $195.92B
- 1M return
- -5.79%
- -6.80%
- 1Y return
- +299.12%
- -45.07%
- Industry
- Biotechnology: Pharmaceutical Preparations
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- News (4w)
- 10
- 8
- Recent ratings
- 15
- 25
Novo Nordisk A/S
Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases. The Biopharmaceuticals segment offers products in the areas of haemophilia, growth disorders, and hormone replacement therapy. The company collaboration agreements with Lund University to develop treatment for Parkinson's diseases; and bluebird bio, Inc. to develop genome editing treatments for children and adult patients. Novo Nordisk A/S also has a research collaboration with Lumen Bioscience, Inc. to explore strategies for delivering oral biologics for cardiometabolic disease. The company was founded in 1923 and is headquartered in Bagsvaerd, Denmark.
Latest BIOA
- SEC Form 4 filed by Director Pande Vijay Satyanand
- SEC Form 4 filed by Director Hemrajani Rekha
- SEC Form 4 filed by Director Healy James
- SEC Form 4 filed by Director Enright Patrick G
- SEC Form 4 filed by Director Davidson Michael H.
- SEC Form 4 filed by Director Garnier Jean Pierre
- BioAge Labs Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
- Roth Capital initiated coverage on BioAge Labs with a new price target
- BioAge Labs to Present at Upcoming Investor Conferences
- Cell-Based Therapies Poised to Disrupt Multi-Billion-Dollar Anti-Aging and Neurodegenerative Markets
Latest NVO
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form SD filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- Peptide-Based Health Industry Positioned for Explosive Long-Term Growth Across Global Wellness Markets
- SEC Form 6-K filed by Novo Nordisk A/S
- SEC Form 6-K filed by Novo Nordisk A/S
- The $59B Quiet Shift Reshaping How Patients Access Care